Stay updated on Indoximod Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Indoximod Combo in Melanoma Clinical Trial page.

Latest updates to the Indoximod Combo in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe page no longer displays a banner announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check10 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check24 days agoChange DetectedAn NIH-wide announcement about website terminology appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check38 days agoChange DetectedThe ClinicalTrials.gov page continues to display a 403 Forbidden error, with the footer showing revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check52 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed trial information with a generic error screen. This blocks access to the trial’s details, contacts, locations, and documents until the issue is resolved.SummaryDifference18%

- Check59 days agoChange DetectedA site-wide revision badge was added (v3.7.0). Melanoma-related glossary entries (Melanoma, related topics:, MedlinePlus Genetics) and an earlier revision note (Revision: v3.6.6) were removed.SummaryDifference0.2%

Stay in the know with updates to Indoximod Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Indoximod Combo in Melanoma Clinical Trial page.